# Urology Times > Urology Times - Healthcare Publication - Base URL: https://www.urologytimes.com - Generated: 2026-10-19T16:06:58.126Z - Content updates: multiple times daily ## Content Access for AI Agents This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML. **Supported content types:** - `text/markdown` — Clean Markdown with YAML frontmatter - `text/plain` — Plain text (same as Markdown) - `text/html` — Default HTML response **Example request:** ``` curl -H "Accept: text/markdown" https://www.urologytimes.com/view/article-slug ``` **YAML frontmatter schema** (returned with every Markdown response): | Field | Type | Description | |-------|------|-------------| | `title` | string | Article headline | | `description` | string | Summary/excerpt (max 300 chars) | | `url` | string | Canonical article URL | | `canonical_url` | string | Canonical URL if different from `url` | | `published` | ISO 8601 | Original publication date | | `modified` | ISO 8601 | Last modification date | | `authors` | string[] | Author display names | | `content_type` | string | Content category (e.g., "News", "Clinical") | | `categories` | string[] | Taxonomy categories | | `tags` | string[] | SEO tags | | `image` | string | Featured image URL | | `publisher` | string | Publication/site name | **Discovery headers** (included on all responses): - `Link: ; rel="llms"` — RFC 8288 link to this file - `X-Llms-Txt: https://www.urologytimes.com/llms.txt` — Explicit discovery header ## Usage Policy - Robots policy: [https://www.urologytimes.com/robots.txt](https://www.urologytimes.com/robots.txt) - Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329) - Rate guidance: prefer RSS and sitemap feeds over crawling individual pages - Attribution: All content © MJH Life Sciences. Include source URLs when citing. ## Content Categories - [Around the Practice](https://www.urologytimes.com/around-the-practice) - [Begin Your Journey: Tackling Burnout](https://www.urologytimes.com/begin-your-journey-tackling-burnout) - [Business](https://www.urologytimes.com/business) - [Clinical](https://www.urologytimes.com/clinical) - [Clinical Consult](https://www.urologytimes.com/clinical-consult) - [Clinical Forums Recaps](https://www.urologytimes.com/clinical-forums-recaps) - [Conference Recaps](https://www.urologytimes.com/conference-recaps) - [Conferences](https://www.urologytimes.com/conference) - [Health Policy](https://www.urologytimes.com/health policy) - [Innovation Celebration](https://www.urologytimes.com/innovation-celebration) - [Interviews](https://www.urologytimes.com/interviews) - [Investigator Perspectives](https://www.urologytimes.com/investigator-perspectives) - [Medical World News](https://www.urologytimes.com/mjh-broadcast-channel) - [News](https://www.urologytimes.com/news) - [Opinion](https://www.urologytimes.com/opinion) - [Peer Exchange](https://www.urologytimes.com/peer-exchange) - [Podcasts](https://www.urologytimes.com/podcasts) - [Publications](https://www.urologytimes.com/publications/[publication]/[year]/[issue]) - [Rapid Readouts](https://www.urologytimes.com/rapid-readouts) - [Readout 360](https://www.urologytimes.com/read-out-360) - [Residents Corner](https://www.urologytimes.com/residents-corner) - [Resources](https://www.urologytimes.com/resources) - [Treatment Landscape Evolutions](https://www.urologytimes.com/treatment-landscape-evolutions) - [UTv](https://www.urologytimes.com/UTv) - [UroView](https://www.urologytimes.com/uroview) - [Video Series](https://www.urologytimes.com/video-series) - [Videos](https://www.urologytimes.com/videos) - [Viewpoints](https://www.urologytimes.com/viewpoints) ## Featured Content - [Managing ARPI-related fatigue: Balancing tolerability and treatment persistence](https://www.urologytimes.com/view/managing-arpi-related-fatigue-balancing-tolerability-and-treatment-persistence): Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adher... - [Prostate Cancer Case Review: Selecting Radioligand Therapy Candidates](https://www.urologytimes.com/view/prostate-cancer-case-review-selecting-radioligand-therapy-candidates): Selecting candidates for radioligand therapy requires more than a positive PSMA scan, and the panel details how tracer avidity, disease volume, and se... - [Prostate Cancer Case Review: PSMA PET Before Definitive Therapy](https://www.urologytimes.com/view/prostate-cancer-case-review-psma-pet-before-definitive-therapy): A high-risk, newly diagnosed patient's PSMA PET results reshape surgical planning, nerve-sparing decisions, and the choice between surgery and radiati... - [Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC](https://www.urologytimes.com/view/anktiva-plus-bcg-shows-durable-responses-in-bcg-unresponsive-nmibc): Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free surviva... - [The UroOnc Minute: Managing Intravesical Therapy Toxicity in NMIBC, With Vignesh Packiam, MD](https://www.urologytimes.com/view/the-uroonc-minute-managing-intravesical-therapy-toxicity-nmibc-with-vignesh-packiam-md): Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder funct... - [Sandip Prasad, MD, on the safety profile of mitomycin intravesical solution](https://www.urologytimes.com/view/sandip-prasad-md-safety-profile-mitomycin-intravesical-solution): Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling d... - [FAQs: The AUA 2025 Guideline on Genitourinary Syndrome of Menopause](https://www.urologytimes.com/view/faqs-the-aua-2025-guideline-on-genitourinary-syndrome-of-menopause): These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline. - [Three-year data show durable responses with mitomycin intravesical solution](https://www.urologytimes.com/view/three-year-data-show-durable-responses-with-mitomycin-intravesial-solution): Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-N... - [Armine K. Smith, MD, on sexual health counseling before cystectomy](https://www.urologytimes.com/view/armine-k-smith-md-on-sexual-health-counseling-before-cystectomy): Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical... - [FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC](https://www.urologytimes.com/view/fda-approves-nogapendekin-alfa-inbakicept-plus-bcg-for-papillary-only-bcg-unresponsive-nmibc): This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors. ## Feeds and Indexes - [RSS Feed](https://www.urologytimes.com/rss.xml): Latest articles in XML syndication format - [Sitemap](https://www.urologytimes.com/sitemap.xml): Complete URL index for all published pages - [News Sitemap](https://www.urologytimes.com/sitemap-news.xml): Recent articles optimized for news indexing - [Authors Directory](https://www.urologytimes.com/authors): Browse all contributors and their published work